(Arg)(9)-SH2 superbinder: a novel promising anticancer therapy to melanoma by blocking phosphotyrosine signaling

BACKGROUND: Melanoma is a malignant tumor with high misdiagnosis rate and poor prognosis. The bio-targeted therapy is a prevailing method in the treatment of melanoma; however, the accompanying drug resistance is inevitable. SH2 superbinder, a triple-mutant of the Src Homology 2 (SH2) domain, shows...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, An-dong, Xu, Hui, Gao, Ya-nan, Luo, Dan-ni, Li, Zhao-feng, Voss, Courtney, Li, Shawn S. C., Cao, Xuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034221/
https://www.ncbi.nlm.nih.gov/pubmed/29976230
http://dx.doi.org/10.1186/s13046-018-0812-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034221/
https://www.ncbi.nlm.nih.gov/pubmed/29976230
http://dx.doi.org/10.1186/s13046-018-0812-5

Ejemplares similares